Skip to main content

Table 2 Gemcitabine pharmacokinetics

From: Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

  All patients (n = 20) Cytidine deaminase genotype subgroups P-valuea (MW) P-valueb (KW)
A/A (n = 8) A/C (n = 8) C/C (n = 4) A/C+C/C (n = 12)
Gemcitabine
Dose (mg) 2,098 (1,935–2,800) 2,199 (1,970–2,400) 2,024 (2,000–2,200) 2,359 (1,935–2,800) 2,093 (1,935–2,800)
AUC0→3 h (mg·h/L) 8.6 (6.0–22.2) 8.7 (6.1–22.2) 8.6 (7.1–17.3) 9.7 (6.0–12.9) 8.6 (6.0–17.3) 0.939 0.988
Vdistribution (L) 72 (37–120) 83 (37–120) 75 (59–105) 52 (39–78) 70 (39–105) 0.316 0.137
Clmetabolic (L/h) 246 (106–466) 251 (106–328) 232 (118–300) 248 (164–466) 232 (118–466) 0.537 0.736
T1/2 elimination (h) 0.22 (0.08–0.48) 0.26 (0.08–0.48) 0.23 (0.17–0.31) 0.16 (0.08–0.21) 0.21 (0.08–0.31) 0.316 0.094
dFdU
AUC0→3 h (mg·h/L) 60.5 (44.6–98.6) 64.7 (46.8–98.6) 55.8 (44.6–71.8) 60.6 (53.9–81.1) 56.1 (44.6–81.1) 0.589 0.648
T 1/2 elimination (h) 2.43 (1.62–5.32) 2.49 (2.09–5.32) 2.14 (1.62–4.25) 2.21 (1.67–3.80) 2.13 (1.62–4.25) 0.190 0.419
  1. Values are medians with the ranges in parentheses
  2. aP-values resulting from the Mann-Whitney (MW) test on the difference between AA versus combined AC+CC genotype
  3. bP-values resulting from the Kruskal-Wallis (KW) test on differences among AA, AC, and CC genotypes